NCT05945108Completed
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER: Multicenter Retrospective Study (Real World Evidence - RWE)
Source: ClinicalTrials.gov · Last updated 11 Apr 2025
Brief summary (registry, in English)
A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 400 (actual)
- First submitted
- 22 Jun 2023
- Start date
- 10 Jul 2023
- Primary completion date
- 18 Apr 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Bladder cancer
- NCT number
- NCT05945108
What you commit to
- Study type: Observational
- Participants enrolled: 400
- From 10 Jul 2023 to the primary completion date, 18 Apr 2024
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Locally advanced muscle-invasive urothelial carcinoma (suspected lymph node impairment in staging imaging tests) or metastatic at diagnosis;
Other
- Low-risk non-muscle invasive urothelial carcinoma (single lesion, pTa and low-grade);
- Bladder carcinoma with non-urothelial histology (adenocarcinoma, squamous-cell carcinoma or small cell carcinoma);
Who the study is looking for
- Age ≥ 18 years old;
- Diagnosis of high-risk non-muscle invasive urothelial carcinoma, defined as:
- T1 tumor and/or high-grade lesion (G3) and/or presence of CIS.
- Multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm);
- Diagnosis of early muscle-invasive urothelial bladder carcinoma (cT2, cT3 or cT4a N0);
- Consent to participate in the study.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Belo Horizonte | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Porto Alegre | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Recife | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | Salvador | Brazil | Unknown status |
| - Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
Related publications
- Treatment Patterns and Outcomes in Localized Urothelial Carcinoma in Middle-Income Countries: A Multicenter Real-World Study.JCO Glob Oncol · 2026 · PMID 42054609
This page is information, not medical advice. Discuss any trial with your doctor.